Clinical studies evaluating the safety, efficacy and tolerability of rapastinel as an adjunctive treatment for major depressive disorder (MDD) did not meet primary and key secondary endpoints, according to topline results announced by Allergan.
Clinical studies evaluating the safety, efficacy and tolerability of rapastinel as an adjunctive treatment for major depressive disorder (MDD) did not meet primary and key secondary endpoints, according to topline results announced by Allergan.
Pharmamarketeer richt zich op marketingprofessionals van farmaceuten en andere medisch-gerelateerde organisaties in Nederland en België.
Copyright 2023 © Uitgave van MedHealth Communications BV | Privacy disclaimer
